
|Videos|September 23, 2020
Management of Adverse Effects in R/R HER2+ mBC
Advertisement
Counseling patients and the management of adverse effects of newer regimens in relapsed/refractory HER2+ metastatic breast cancer as well as advice for oncology nurses.
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient mHSPC
2
Luspatercept Misses Primary RBC-TI End Point But Shows Clinically Meaningful Improvement for Anemia in Myelofibrosis
3
MONUMENTAL-3 Data Support Talquetamab Plus Daratumumab ± Pomalidomide as a New SOC in R/R Myeloma
4
CLL14 Final Analysis Shows Long-Term PFS Gain With Venetoclax/Obinutuzumab in Previously Untreated CLL
5











































































